Shionogi
Clinical trials sponsored by Shionogi, explained in plain language.
-
New antibiotic shows promise for kids with tough infections
Disease control CompletedThis study tested the safety and how the body handles the antibiotic cefiderocol in 53 hospitalized children aged 3 months to 18 years with serious bacterial infections. The goal was to see if the drug is safe and how it works in the body. Results help doctors understand dosing a…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New COVID pill shows promise in early trial
Disease control CompletedThis study tested an experimental antiviral drug called S-892216 in 282 adults with mild-to-moderate COVID-19. The goal was to see if the drug could lower the amount of virus in the nose and throat faster than a placebo. Participants had to have symptoms and a positive test for t…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New antibiotic studied in newborns to fight tough infections
Disease control CompletedThis study looked at how the antibiotic cefiderocol works in newborns up to 3 months old with serious bacterial infections. Researchers measured how the drug moves through the body and checked for side effects. The goal was to find safe and effective dosing for this vulnerable ag…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New COVID-19 vaccine shows promise in massive trial
Prevention CompletedThis study tested a new vaccine called S-268019 to see if it could prevent COVID-19. About 9,900 adults who had never had COVID-19 received either the vaccine or a placebo. Researchers tracked how many people got sick with COVID-19 after vaccination to measure the vaccine's effec…
Phase: PHASE3 • Sponsor: Shionogi • Aim: Prevention
Last updated May 22, 2026 13:52 UTC
-
New COVID pill shows promise in shortening symptoms
Symptom relief CompletedThis study tested an experimental antiviral pill called S-217622 in over 2,000 adults with mild to moderate COVID-19 who were not hospitalized. Participants started the pill within 3 days of symptoms. The goal was to see if the pill could shorten symptom duration and lower virus …
Phase: PHASE3 • Sponsor: Shionogi • Aim: Symptom relief
Last updated May 18, 2026 12:13 UTC
-
Liver function and drug processing: a new study on BPN14770
Knowledge-focused CompletedThis study looked at how the drug BPN14770 is handled by the body in people with different levels of liver impairment (mild, moderate, severe) compared to healthy volunteers. A total of 32 adults took a single dose of the drug. The main goal was to measure drug levels in the bloo…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated May 26, 2026 07:57 UTC
-
New drug S-740792 passes early safety tests in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety and how the body handles a new drug called S-740792 in 99 healthy adults. Researchers gave single and multiple doses, checked the effect of food, and looked for interactions with another drug. The goal was to gather basic safety informatio…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated May 26, 2026 07:25 UTC
-
Kidney drug study: how does BPN14770 affect patients?
Knowledge-focused CompletedThis study looked at how the drug BPN14770 is processed by the body in people with severe kidney impairment compared to healthy volunteers. Fourteen participants took a single dose, and researchers measured drug levels and checked for side effects. The goal was to understand if k…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated May 18, 2026 11:58 UTC